Russian Federation: Changes To Federal Law 61-FZ On The Circulation Of Medicines And The RF Law On Veterinary Medicine

Last Updated: 20 July 2015
Article by Anna McDonald

Changes to Federal Law 61-FZ on the Circulation of Medicines

On July 13, 2015 a new set of amendments to Federal Law No. 61-FZ on the Circulation of Medicines of April 12, 2010 was approved by Federal Law No. 241-FZ on Amendments to the Federal Law on the Circulation of Medicines (hereinafter "Law 241-FZ"). The amendments have become the subject of criticism due to a number of provisions of Law 241-FZ.

Law 241-FZ clarifies in particular the set of documents required to confirm state registration of a pharmaceutical for medical application, whether such confirmation is requested before or after January 1, 2016. At the same time, the list of documents required for the respective application after January 1, 2016 includes a copy of a report on the pharmaceutical manufacturer's compliance with the good manufacturing practice rules (hereinafter the Rules) to be issued by the RF Ministry of Industry and Trade. Considering the number of manufacturers to be audited for such compliance, and also the novelty of this requirement and the absence of an approved procedure for carrying out such audits by the Ministry of Industry and Trade, it seems unlikely that the audit of all manufacturers will be successfully completed by the end of 2015. At the same time, foreign manufacturers of pharmaceuticals for veterinary use may submit a report on compliance with the Rules from a competent body of the manufacturer's country by 2017. Accordingly, unless the said deadline is postponed until a later date, the registration of pharmaceutical products for medicinal use by Russian manufacturers after January 1, 2016 may become impossible in practice and, therefore, no new pharmaceutical products will enter the market.

Further difficulties are created by the change in definition of the term "reference drug." That term introduced on July 1, 2015 means a drug that is registered for the first time, the quality, efficacy and safety of which have been proven on the basis of results of pre-clinical and clinical trials, and which is used to evaluate the bioequivalence or therapeutic equivalence, quality, efficacy and safety of a generic or analogue (biologically similar) drug. According to Law 241-FZ, a reference drug must go through the trials stipulated by Federal Law No. 429-FZ on Amendments to the Federal Law on the Circulation of Medicines of December 22, 2014 (hereinafter "Law 429-FZ"), including those of its provisions which are entering into force in 2016. This formally makes it impossible to register a drug as a reference drug before 2016. To prevent a collision between the above-mentioned provisions of law, Law 241-FZ clarifies that until January 1, 2016 an original drug shall be considered as the reference drug. It is worth noting that the very term "original drug" (apparently intended for applying Law 241-FZ) has already been removed from the legislation. According to comments from the Director of the Department of Drug Supply and Regulation of the Circulation of Medical Devices of the Russian Ministry of Health Yelena Maksimkina1, although the term was removed from the law, original drugs that have already been registered will retain their status and will be used as reference drugs. One can only hope that the Russian Health Ministry will indeed follow this principle in practice when registering pharmaceuticals.

At the same time, Law 241-FZ emphasizes the status of reference drugs for veterinary use, clarifying that such drugs must go through pre-clinical and clinical trials in accordance with the requirements established for veterinary drugs. In general, a number of provisions of law are made more detailed by Law 241-FZ, specifically regarding pharmaceuticals for veterinary use. For example, the list of documents to be sent together with the terms of reference for expert review of a veterinary pharmaceutical has been clarified, a procedure for completing the application for confirmation of state registration of a veterinary drug and the documents attached to the application has been detailed.

In addition to this, Law 241-FZ clarifies a number of provisions regarding the powers and interaction of government agencies, including for setting prices on so-called essential (vital) drugs. In order to get expedited expert review of drugs the order of applications for state registration is defined as under one international nonproprietary name of the drug or drug grouping name.

Law 241-FZ also indicates the sequence of actions to be taken when violations of the rules are discovered during the clinical trial of a drug. If such violations affect the completeness and accuracy of the clinical trial, then the competent body (the Federal Healthcare Supervisory Service) suspends the trial and issues an order to remedy the violations. If the medical organization conducting the trial fails to remedy the violations within the stated time period, a decision is taken to stop that trial.

It is also clarified that state registration of drugs for which applications are filed before the effective date of Law 429-FZ, and review of applications for state expert review of drugs filed before the effective date of Law 429-FZ follow the rules of law in effect prior to the entry into force of Law 429-FZ.

Changes to the Russian Federation Law on Veterinary Medicine

On July 1, 2015 the State Duma adopted in the third reading, and on July 8 the Federation Council approved the Federal Law on Amendments to the Russian Federation Law on Veterinary Medicine and Certain Legislative Acts of the Russian Federation. That Federal Law introduces significant changes to the legislation on veterinary medicine.

In particular, it is planned that the Russian Federation Ministry of Agriculture will adopt veterinary regulations governing all areas of veterinary medicine and various types of veterinary activity.

Also, it is intended to create the Federal State Veterinary Information System in which veterinary documents accompanying the products will be generated electronically (which will be mandatory starting January 1, 2018). The Law sets out the principle that veterinary supporting documents will be generated free of charge and that the competent governmental body has the duty to issue them in hard copy at the request of the owner of the product covered by the veterinary control requirement.

The Law obliges the RF Government to develop and approve a procedure for creating, developing and operating the Federal State Veterinary Information System, although it does not set the deadline for such procedure to be put in place. It is also provided that such procedure shall contain requirements to ensure access of individuals and legal entities to information contained in the Federal State Veterinary Information System, to enter information in the system, to obtain information from the system and register those entities in the system.

The Federal State Veterinary Information System will contain, in particular, information about pharmaceuticals, feeds and feed supplements for animals. Inasmuch as the Law does not provide for any provisions governing the procedure for entering data on pharmaceuticals, feeds and feed supplements for animals that have already been registered in that Federal System, it would be reasonable to suppose that such provisions will be included in the procedure for creating, developing and operating the said Federal Veterinary Information System, which the RF Government is responsible for developing and approving, as mentioned above.



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Oct 2018, Other, Munich, Germany

Please register via RSVP button by October 15, 2018. If you have any questions, please contact Marcel Schmidt.

30 Oct 2018, Other, Frankfurt, Germany

With the blockchain market maturing, we see an advancing diversification of token types and offerings.

30 Oct 2018, Other, London, UK

The third campaign in Dentons' TechTalk series explores the role of Blockchain in the modern business world.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions